-
Building a Biotech Board
On our 12+ year journey here at Kineticos, we have come to recognize that one reason great science is often -
Bridges and Barriers to Advancing CAR T Therapy
Kineticos’ Operating Executive, Steve Buckanavage, recently caught up with Dr. Jeffrey Skolnik, VP of Clinical Development at Inovio Pharmaceuticals to -
Are we Manufacturing the right T-Cells And a Look at the Future of Oncology Precision Medicine
The final part of the discussion between Kineticos’ Operating Executive, Steve Buckanavage and Precision Biosciences’ CMO, Christopher Heery M.D., covers -
Is Precision Medicine in Oncology Narrowing Patient Population Too Much?
Kineticos’ Operating Executive Steve Buckanavage, continues his discussion with Christopher Heery, M.D., CMO at Precision Biosciences as they tackle the -
Can We Create Companion Diagnostics In Oncology With What We Know About Biomarkers?
As we continue our discussion between Steve Buckanavage, Kineticos’ Operating Executive and Christopher Heery, M.D., CMO at Precision Biosciences, we -
Are Checkpoint Inhibitors Impacting How We Cure Disease?
Throughout September and October, we have been discussing Precision Medicine and it’s impact on various segments of the life sciences.
The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels. Our consulting team has a depth of expertise across functional areas and therapeutic areas, established through decades of work in consulting or in industry. Overall the practice has a strong commitment to client satisfaction and a proven ability to deliver results through practical solutions.
The Biopharmaceutical Practice at Kineticos supports clients across three service areas including:
Corporate Strategy & Development
- Business Model Design
- Portfolio Strategy
- Geographic Market Entry Strategy
- Opportunity Assessment
- In- and Out- Licensing
- Private Financing
Medical Affairs Strategy
- Medical Affairs Strategic Planning & Operations
- MSL Architecture, Management and Support
- Real World Evidence/Registry Study
Commercial Strategy
- New Product Planning
- Strategic Launch Planning
- Post-Marketing Strategy and Planning
- Lifecycle Management
- Marketing Excellence
Regulatory
- Regulatory Strategy
- Product Development
- Regulatory Operations & Submissions Management
Click the Tabs Below for Biopharmaceutical Practice Case Studies, White Papers and Articles, and Blog
-
R&D Strategy
Situation: A publicly traded biopharmaceutical company with a novel technology platform approached Kineticos about supporting their R&D strategy. The organization -
Portfolio Optimization
Situation: A fully integrated pharmaceutical company developing a class of immuno-oncology therapies was in need of a deeper understanding of -
Portfolio Prioritization – Oncology
Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. -
Oncology Commercial Assessment – Melanoma
Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the -
Business Development & Licensing
Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and -
Product Search
Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and
-
Growth by Acquisition in Life Sciences: Do You Have a Plan?
Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as -
R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation
James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation? -
Merck KGaA and Bayer Choose Opposite Strategies
Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent -
Foundation Medicine and Clovis Expand Partnership
Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion -
Role of Companion Diagnostics in Immuno-oncology Race Unfolding
Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies -
Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity
Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its